AVE9633

DB06318InvestigationalProtein Based Therapies

AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.

Mechanism: Pharmacologically active on Myeloid cell surface antigen CD33
Curator reviewed
Primary indication: Investigated for use/treatment in leukemia (myeloid).Curator reviewed
Code names: AVE-9633

Resolves to

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

696Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with AVE9633, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.